Rankings
▼
Calendar
RCKT Q4 2023 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RCKT
Rocket Pharmaceuticals, Inc.
$572M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$63M
Net Income
-$60M
EPS (Diluted)
$-0.64
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$34M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$566M
Total Liabilities
$74M
Stockholders' Equity
$493M
Cash & Equivalents
$56M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$63M
-$69M
+8.4%
Net Income
-$60M
-$67M
+10.6%
← FY 2023
All Quarters
Q1 2024 →